1.Preparation and Study of Monoclonal Antibodies to Human Lung Cancers
Journal of Kunming Medical University 1988;0(03):-
Yunnan Gejiu lung adenocarcinoma cell line,i.e GLC,is used as the immunogen in this paper, Three hybridomas F19,N-35,STA-2,secreating McAb to human lung cancers have been established.After a long period cultured,their secreation of McAb are stable.A large number of human tissues have been tested and observd with the techniques of immunal cytochemistry and histochemistry.The clinical potentials of applycation of these three McAbs have also been studied.
2.Research advances in effects of general anesthetics on central nervous system of pediatric patients and immature animals
Journal of Shanghai Jiaotong University(medical Science) 2010;30(2):233-235
Long-term or even permanent neuronal injury can follow administration of general anesthetics.It has been confirmed that some elderly patients may experience a decline in cognitive function after general anesthesia.However,the effects of general anesthetics on the central nervous system have not been determined yet.Here we summarize the effects of general anesthetics on the central nervous system in pediatric patients and immature animals.
3.Changes of levels of CD4+CD25+Foxp3+regulatory T cells in HDCP peripheral blood and its significance
Chinese Journal of Immunology 2015;(9):1253-1256
Objective:To investigate the changes of the levels of CD 4+CD25+Foxp3+regulatory T cells in HDCP peripheral blood and its significance.Methods: From 2013 January to 2014 August 46 hypertensive disorder complicating pregnancy ( HDCP ) patients treated in our hospital ,including 22 patients with mild preeclampsia ,24 cases of severe preeclampsia ,and 25 normal pregnant women,used flow cytometry detected each group patient peripheral blood CD 4+CD25+Foxp3+regulatory T cells.Results: Severe preeclampsia group CD4+CD25+T cell ratio was (5.01±1.04)%,lower than mild preeclampsia group (7.38±1.26)% and normal pregnant women group ( 12.59 ±2.48 )%, the difference was statistically significant ( P<0.05 );Mild preeclampsia and severe preeclampsia group CD4+CD25+Foxp3+T cell absolute number respectively were (0.96±0.11) ×107 and (0.63±0.12) ×107,CD4+CD25+Foxp3+Treg/CD4+T were (2.58±0.93)%and (1.84±0.85)%,were lower than that of normal pregnant women group (1.85± 0.17) ×107 and(5.11±0.99)%,the difference was statistically significant (P<0.05);Mild preeclampsia group and severe preeclampsia blood estriol were (6.16±2.17) mg/L and (3.27±1.15) mg/L,significantly lower than that of normal pregnant women group (11.34±2.4) mg/L,the difference was statistically significant (P<0.05).Conclusion: Hypertensive disorder complicating pregnancy diseases patient CD 4+CD25+Foxp3+regulatory T cells was significantly reduced ,but also serum estriol reduced ,which may be related to the pathogenesis of gestational hypertension disease and immune tolerance .
4.Primary angiitis of the central nervous system
Chinese Journal of Neurology 2021;54(4):392-398
Primary angiitis of the central nervous system is relatively rare. In recent years, research of the disease in neuroimaging, differential diagnosis, treatment and other aspects advanced greatly. This paper provided a systematic review of this disease entity in order to promote neurologists, neurosurgeons and radiologists′ experience in the diagnosis and treatment of the disease.
5.Advance in the study of targeting delivery system for siRNA mediated by aptamers.
Xiaolin WANG ; Qingqing WANG ; Haifeng SONG
Acta Pharmaceutica Sinica 2012;47(7):850-5
RNA interference (RNAi), as a new technology of gene therapy, has been used in the studies of many diseases in vitro, however, targeting delivery of small interference RNA (siRNA) is still a bottleneck for clinical therapy of siRNA agents. Aptamer is a group of oligonucleotides with high affinity and targeting, and is becoming another important means of delivery for siRNA. In this review, we summarized siRNA delivery obstacles in vivo and recent attractive developments increatively using cell-internalizing aptamers to deliver siRNAs to target cells.
6.Effect of patients with anxiety and depression in elderly patients with hypertension antihypertensive effect of psychological intervention combined with Flupentixol and Melitracen Tablets
Qingqing SUN ; Wei WANG ; Lihua WANG
Chinese Journal of Biochemical Pharmaceutics 2017;37(7):280-281
Objective To study the influence analysis of patients with anxiety and depression in elderly patients with hypertension antihypertensive effect of psychological intervention combined with Flupentixol and Melitracen Tablets.Methods 60 elderly patients with hypertension accompanied by anxiety and depression in our hospital from January 2014 to December 2016 were selected as the subjects.They were randomly divided into the control group and the experimental group, with 30 patients in each group.The control group was treated with conventional antihypertensive treatment, the experimental group were given psychological intervention combined with treatment of Flupentixol and Melitracen Tablets.The clinical indexes of the experimental group and the control group were compared and analyzed.Results After the corresponding treatment, the effective rate of antihypertensive treatment in the experimental group was 28 cases, and the effective rate of depressurization was 93.3%.The effective rate of antihypertensive treatment in the control group was 21, and the effective rate of antihypertensive treatment was 70%.After treatment, the HAMD score and HAMA score of the experimental group were significantly lower than those before the treatment, and the score of the experimental group was significantly lower than that of the control group, with statistical difference(P<0.05).Conclusion The treatment of elderly hypertensive patients with anxiety and depression in patients with better antihypertensive effect of psychological intervention combined with Flupentixol and Melitracen Tablets, can improve the depression and anxiety of patients in a large extent, high safety, is further applied in clinical significance.
7.Change of the Nrf2-ARE pathway in the process of autophagy and its effect on hepatic carcinoma cell cycle
Qingqing SHI ; Shiming WANG ; Xiushan DONG
International Journal of Surgery 2012;(12):849-852
Hepatic carcinoma is one of the most common malignant tumors in China.Autophagy activity and the change of Nrf2-ARE pathway play an important role in the process of liver tumors.Nrf2 which is an important regulator to liver cancer belongs to the CNC family.Research discovered that after the inhibition of autophagy,Nrf2-ARE pathway activation contributes to the progression of hepatocellular carcinoma.This article summarizes the relationship between autophagy and the Nrf2-ARE pathway and its impact on the hepatic carcinoma.
8.Establishment and practice of quality standards for ward-rounds headed by department head of internal medicine
Tao LIU ; Qingqing FAN ; Aiqin WANG
Chinese Journal of Hospital Administration 2013;29(12):900-902
Difficult cases are frequently found at the department of internal medicine of large hospitals.Better quality of ward-rounds by these department heads is key to medical safety,to better operations,and to reducing medical disputes incurred by malpractice.Focusing on standardizing wardround behavior and medical records,the People's Liberation Army General Hospital established and applied the Quality Standards of Ward-rounds on difficulty cases,which scored expected outcomes of better quality of care and better patient satisfaction.
9.Preliminary study on antitumor effect of C215gene transfected tumor vaccine and monoclonal antibody-superantigen fusion protein C 215Fab-SEA
Qingqing WANG ; Hai YU ; Da YU
Chinese Journal of Immunology 2001;17(2):76-78
Objective:To investigate the anti-tumor effect of C215gene transfected tumor vaccin e and monoclonal antibody-superantigen fusion protein C215Fab-SEA.Methods:B16 melonoma cells were transfected with the gene encoding a human colon adenoca rcinoma cell-surface glycoprotein C215 to produce a tumor vaccine,melanom a models were established in C57BL/6 mice to observe the antitumor effect of the tumor vaccine and the fusion protein C215Fab-SEA.Results:Tumor growth in mice treated with the vaccine tog e ther with the fusion protein C215Fab-SEA was significantly inhibited comp ared with the control group(P<0.01),while the tumor growth in group treate d wi th the vaccine only and group treated with the fusion protein only were not obvi ously inhibited compared with the controls.Conclusion:The fusion protein C215Fab-SEA could enh ance the effect of C215-transfected tumor vaccine against the growth of C 215-negative tumors.
10.A long-term follow-up study on the treatment of small cell lung cancer using teniposide/carboplatin with etoposide/carboplatin as first-line therapy
Qingqing CHEN ; Huilai ZHANG ; Huaqing WANG
Tianjin Medical Journal 2015;(7):788-791
Objective To compare the efficacy and adverse reaction of teniposide (VM-26) plus carboplatin (TC regimen) and etoposide (VP-16) plus carboplatin (EC regimen) in treatment of newly diagnosed small cell lung cancer (SCLC), and the possible role of VM-26 on prevention of brain metastasis of SCLC. Methods A total of 102 previously untreated SCLC patients without brain metastasis were divided into VP-16 group received EC regimen (n=64) and VM-26 group received TC regimen(n=38). The carboplatin dosages in two groups were calculated by blood concentration-area under the curve(AUC)=5, and intravenous infusion of 1 h for the first day. In VM-26 group, VM-26 70 mg/m2+normal saline 500 mL was intravenously infused of 2 h for 1-3 days. VP-16 100 mg/m2+normal saline 500 mL was given to VP-16 group, 1 h for 1-3 days. Twenty-one day was for 1 treatment cycle. The curative effect, prognosis and adverse reaction were compared between two groups. Results The overall response rates (ORR) and disease control rates (DCR) were 78.9%(30/38) and 97.4%(37/38) in VM-26 group, respectively, and 76.6%(49/64) and 95.3%(61/64) in VP-16 group, respectively, with no significant differences between the two groups (χ2=0.078 and 0.283, P<0.05). The median progression-free survival (PFS) was 10 months (95%CI 7.4-12.6) in VM-26 group and 9 months (95%CI 6.4-11.6) in VP-16 group (χ2=0.029,P=0.866). The median overall survival (OS) was 18 months (95%CI 16.5-19.5) and 16 months (95%CI 9.9-22.1) in VM-26 group and VP-16 group (χ2=0.217,P=0.642), respectively. The survival rates for 1,2 and 3 years were 73.7%, 36.8%and 18.4%in VM-26 group, and 71.9%, 37.5%and 18.8%in VP-16 group, respectively, with no significant differences between the two groups (P>0.05). The brain metastasis rate was significantly higher in VP-16 group [43.8%(28/64)] than that of VP-26 group [21.1%(8/38),χ2=5.379,P=0.02). The adverse reactions were mainly grade 1/2 bone marrow suppression in two groups. Conclusion TC is a highly active regimen for treatment of SCLC. There is no difference in the ef?fectiveness and adverse reactions versus EC. Application of VM-26 can reduce the incidence of brain metastasis in SCLC patients.